N-[(4S)-1-cyclobutyl-3,3-dimethylpiperidin-4-yl]-2-[(3R)-4-(4-methylphenyl)sulfonyl-2-oxo-1,3-dihydropyrazin-3-yl]acetamide | 941815-67-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[(4S)-1-cyclobutyl-3,3-dimethylpiperidin-4-yl]-2-[(3R)-4-(4-methylphenyl)sulfonyl-2-oxo-1,3-dihydropyrazin-3-yl]acetamide
• CAS: 941815-67-4
• 化学式: C₂₄H₃₄N₄O₄S
• 分子量: 474.624
• InChiKey: ZXIYSBLLGAZRTM-RTWAWAEBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (R)-2-(3-oxo-1-tosyl-1,2,3,4-tetrahydropyrazin-2-yl)acetic acid 在 盐酸 、 三乙酰氧基硼氢化钠 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 水 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-[(4S)-1-cyclobutyl-3,3-dimethylpiperidin-4-yl]-2-[(3R)-4-(4-methylphenyl)sulfonyl-2-oxo-1,3-dihydropyrazin-3-yl]acetamide
  参考文献：
  名称：

  Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency

  摘要：

  In a series of bradykinin B1 antagonists, we discovered that replacement of oxopiperazine acetamides with dehydro-oxopiperazine acetamides provided compounds with enhanced activity against the B1 receptor. The synthesis and SAR leading to potent analogs with reduced molecular weight will be discussed. (C) 2011 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.11.112

文献信息

• Bradykinin 1 Receptor Antagonists
  申请人：Zhu Jiawang

  公开号：US20090227601A1

  公开（公告）日：2009-09-10

  The invention encompasses novel compounds and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for treatment of diseases mediated by B1 bradykinin receptor.

  该发明涵盖了新型化合物及其药学上可接受的衍生物，药物组合物以及治疗由B1布雷金因子受体介导的疾病的方法。
• BRADYKININ 1 RECEPTOR ANTAGONISTS
  申请人：Amgen Inc.

  公开号：EP1963285A1

  公开（公告）日：2008-09-03
• [EN] BRADYKININ 1 RECEPTOR ANTAGONISTS<br/>[FR] NOUVEAUX ANTAGONISTES DE RECEPTEUR DE BRADYKININE 1
  申请人：AMGEN INC

  公开号：WO2007067629A1

  公开（公告）日：2007-06-14

  [EN] The invention encompasses novel compounds and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for treatment of diseases mediated by B1 bradykinin receptor.
  [FR] La présente invention concerne de nouveaux composés et des dérivés pharmaceutiquement acceptables de ceux-ci, des compositions pharmaceutiques et des procédés pour le traitement de maladies médiées par le récepteur de la bradykinine B1.
• Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency
  作者：Wenyuan Qian、Jian Jeffrey Chen、Jason Human、Toshihiro Aya、Jiawang Zhu、Kaustav Biswas、Tanya Peterkin、Randall W. Hungate、Leyla Arik、Eileen Johnson、Gondi Kumar、Smriti Joseph、Janan Jona、Hong-Xun Guo、Zufan Wu

  DOI：10.1016/j.bmcl.2011.11.112

  日期：2012.1

  In a series of bradykinin B1 antagonists, we discovered that replacement of oxopiperazine acetamides with dehydro-oxopiperazine acetamides provided compounds with enhanced activity against the B1 receptor. The synthesis and SAR leading to potent analogs with reduced molecular weight will be discussed. (C) 2011 Published by Elsevier Ltd.